eyeDNA Therapeutics to Present 2-year Follow-up Phase I/II Data on its Investigational Gene Therapy HORA-PDE6b for Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
2024年4月25日 - 7:00PM
Paris, France, April 25, 2024 –
eyeDNA Therapeutics (‘eyeDNA’), a newly created subsidiary of Coave
Therapeutics (‘Coave’), a genetic medicine company focused on
developing life-changing therapies, announces that updated 12-month
and new 24-month follow-up results from its Phase I/II study
evaluating the safety and efficacy of HORA-PDE6b, its
investigational gene therapy for retinitis pigmentosa (RP) caused
by bi-allelic mutations in the PDE6B gene (PDE6b RP) will be
presented during oral presentations at the Association for Research
in Vision and Ophthalmology (ARVO) 2024 meeting in Seattle, WA, USA
(May 5-9, 2024).
Oral presentation details are as follows:
- Abstract Title:
12-month Safety and Efficacy Evaluation of HORA-PDE6B, a Gene
Therapy Targeting Patients with Retinitis Pigmentosa Due to
Biallelic PDE6B Gene Mutation
- Presentation
Number: 2134
- Poster Session and
Number: Retinitis Pigmentosa, 236
- Date & Time:
Monday, May 6, 2024; 3:30 PM – 3:45 PM Pacific Daylight Time
- Room: 612 (Seattle
Convention Center – Arch Building)
- Presenter: Dr
Jean-Baptiste Ducloyer, MD, Nantes University Department of
Ophthalmology, France
The abstract is available online via the ARVO 2024 meeting
online planner:
https://www.arvo.org/annual-meeting/program/online-planner/
***
About eyeDNA Therapeutics and
HORA-PDE6b
eyeDNA Therapeutics, a wholly owned subsidiary
of Coave Therapeutics, is a clinical-stage gene therapy company,
focused on developing life-changing therapeutics for inherited
retinal disorders. Our lead program HORA-PDE6b, an AAV5-based gene
replacement therapy, is being evaluated in a Phase I/II trial for
the treatment of retinitis pigmentosa (RP) caused by bi-allelic
mutations of the PDE6b gene (PDE6b RP).
eyeDNA and Théa Open Innovation (‘TOI’) are
partners for the development and commercialization of HORA-PDE6b.
eyeDNA is responsible for the global development of HORA-PDE6b and
retains commercial rights to the product in the US, Japan, South
Korea, China and other territories outside Europe. In Europe and
certain other countries, HORA-PDE6b is being co-developed by Coave
and Théa Open Innovation under a license and development agreement
with exclusive rights granted to TOI to commercialize CTx-PDE6b in
these territories.
About Coave
Therapeutics
At Coave Therapeutics, we are leading the
transition of genetic medicine from rare to prevalent conditions,
starting with neurodegenerative and eye diseases. Our proprietary
ALIGATER™ (Advanced Vectors-Ligand Conjugates) platform introduces
chemical modifications onto AAV capsids or Lipid Nanoparticles
(LNPs) to overcome the limitations of current vectors on efficacy,
safety, and manufacturability.
With low doses and optimized routes of
administration, our conjugated vectors have demonstrated markedly
improved transduction and biodistribution in the central nervous
system and the eye across different species. Our diverse pipeline
of novel genetic medicines can potentially transform the lives of
people afflicted by rare and prevalent neurodegenerative and ocular
diseases – including genetically and non-genetically defined
indications.
Coave recently created its subsidiary eyeDNA
Therapeutics to focus on the development – up to the marketing
authorization application – of its unique gene therapy HORA-PDE6B
for the treatment of inherited retinal diseases caused by mutations
in the human PDE6B gene.
Headquartered in Paris, France, Coave
Therapeutics is backed by leading international life sciences
investors. For more information about the science, pipeline, and
people, please visit https://coavetx.com/ and follow us on
LinkedIn.
CONTACTS eyeDNA
Therapeutics and Coave Therapeutics Rodolphe Clerval,
CEO contact@coavetx.com
MEDiSTRAVA Sylvie Berrebi,
Leila Adlam, Mark
Swallow coavetx@medistrava.com Tel: +44 (0)203 928
6900